Expanded Access to Venetoclax

Study Identifier
C16-431
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Blood Cancer - Chronic Lymphocytic Leukemia (CLL)
  • Blood Cancer - Multiple Myeloma
  • Blood Cancer - Acute Myeloid Leukemia (AML)
  • Blood Cancer - Non-Hodgkin's Lymphoma (General)
  • Blood Cancer - Acute Lymphoblastic Leukemia (ALL)
  • Amyloidosis
  • Blood Cancer - Leukemia (Other)
  • Study Drug
  • Venetoclax
  • Phase
    N/A
    Sex
    Female & Male
    Age
    N/A

    Protocol Summary

    This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

    Study Locations

    No locations found.